Compare Novo Nordisk A/S (NVO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Starbucks Corp — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Starbucks Corp trades at $104.04 (market cap $119.45B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | SBUX | |
|---|---|---|
Market Cap | $220.53B | $119.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $108.37 |
52-Week Low | $35.29 | $78.46 |
Enterprise Value | $239.49B | $142.14B |
Dividend Yield | 3.63% | 2.37% |
Volume | — | 7,493,833 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Starbucks (SBUX) trades at $104.45, down 0.99% today, near its 52-week high with a bullish technical trend. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $37.18B in 2025, though net income fell to $1.86B, reflecting margin pressures. Analysts maintain a buy consensus with a $108.86 target, citing turnaround progress and cost-saving initiatives, including AI-driven software reductions.
SBUX's outlook is cautiously optimistic, supported by traffic growth and raised 2026 guidance, but profitability remains a concern with a high P/E of 80.01. Key risks include intense competition from Luckin Coffee and macroeconomic sensitivity. Institutional sentiment is positive, with 47% buy ratings, though investors should monitor execution on margin recovery and cost efficiency targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
